Select Page

Tackling RSV: Raising awareness, driving prevention

Respiratory syncytial virus (RSV) is a common respiratory virus and is often misunderstood to be only a childhood illness.  However, older adults and those with chronic conditions constitute a large at-risk population for serious complications from RSVs, including lower respiratory illness.  Every year, the RSV results in many older adults experiencing life-altering consequences, with estimates of 470,000 hospitalizations and 33,000 deaths in those aged 60 years and over in high-income countries, in 2019.  Despite such staggering numbers and the growing evidence indicating that RSV may compare to influenza disease, there is a significant underestimation of the disease burden in older adults.

In May 2023, the US Food and Drug Administration approved Arexvy and Abrysvo vaccines for the prevention of RSV lower respiratory tract disease (LRTD) for use in adults aged 60 years and over.  Arexvy is authorized for use in Canada.  RSV vaccines help protect older adults against severe illness, with clinical trials demonstrating 82.6% efficacy in older adults and 94.6% in individuals with underlying medical conditions.  The RSV-associated morbidity and healthcare costs could be decreased substantially with the use of vaccines.

The coronavirus pandemic provided a stark reminder that vaccines are one of the most effective public health interventions of our time, saving and improving the quality of lives of millions, each year.  RSV is a respiratory virus, with dire consequences on the lives of those most at risk.  With RSV being the most important cause of viral lower respiratory tract illness, it is crucial to disseminate the benefits of the newly approved vaccine for older adults and raise awareness of RSVs as a vaccine-preventable disease and encourage those most at risk to speak to their healthcare providers.

References

RSV PODCAST SERIES “TACKLING RSV: RAISING AWARENESS, DRIVING PREVENTION”  |  PART ONE

A Clinician’s Perspective with Dr. Christine Palmay.

 

 

 

 

 

 

 

 

 

 

 

xyz

 

RSV PODCAST SERIES “TACKLING RSV: RAISING AWARENESS, DRIVING PREVENTION”  |  PART TWO

Patient Testimony

 

 

 

 

 

 

 

 

Dr Alan Kaplan | 10 November 2023
IFA #GlobalCafé |  “Tackling RSV: Raising Awareness, Driving Prevention.”

Join the IFA in promoting awareness of RSV Infection, and the importance of prevention through utilizing vaccination by learning more and sharing information throughout your networks!

Please click on the image below to download the Press Release.

Click on the image below to download it in high resolution.

 

The RSV campaign message bank is a collection of fully built-out content ready to be scheduled during the campaign with relevant key messages and tags.

Instructions:

  1. Please click on the image below. It’ll take you to the RSV’s message bank
  2. Double-click on the message you wish to share and a pop-up window will appear
  3. Copy the text and paste it on your Social Media Channel of choice along with the hashtags #Older adults , #RSV  and #RSVvaccination.

Thank you for helping drive the change!

Click on the image below to download it in high resolution.

This project has been supported by an unrestricted educational grant from
Share This